Rituximab as first-line adjuvant therapy for pemphigus: Retrospective analysis of long-term outcomes at a single center To the Editor: Rituximab has been widely used for treatment-refractory pemphigus, but the experience of its use as a first-line steroid-sparing agent is limited. 1, 2 In this retrospective study we assessed whether use of rituximab early in the disease course would improve the long-term clinical outcome.
All patients with pemphigus vulgaris and pemphigus foliaceus who were evaluated between January 2008 and December 2016 at our institute and systematically treated with rituximab were included. Group A encompassed patients who received rituximab as a first-line steroid-sparing adjuvant within 6 months of diagnosis without any conventional immunosuppresants. Group B consisted of patients with disease activity who received rituximab after failing treatment with corticosteroids/conventional immunosuppressants or for relapse after them. Patients in both groups were treated with 2 infusions of 1000 mg of rituximab 2 weeks apart. Patients who relapsed or failed to achieve complete remission (CR) 3 in 6 months were re-treated with a single infusion (1000 mg) of rituximab. In addition, patients in both groups received oral corticosteroids in the form of a starting dose of prednisolone between 0.5 to 1 mg/kg, invariably with a quick taper and withdrawal of the corticosteroids within 6 months depending on the severity of the disease and clinical judgment.
The primary aim was to compare the efficacy between the 2 groups in terms of achieving CR off therapy. The secondary outcomes were CR when receiving minimal therapy, relapse rate, requirement of repeat infusions, and rituximab-related adverse events. 3 The baseline characteristics of the 2 groups are summarized in Table I . In all, 7 of 9 patients in group A (estimated cumulative rate, 87.5%) and 12 of 20 patients in group B (estimated cumulative rate, 66.2%) achieved CR off therapy (P ¼ .01). After accounting for the effect of disease duration, the hazard ratio between the 2 groups was still statistically significant (hazard ratio, 6.10; 95% confidence interval, 1.52-24.44; P ¼ .01).
When both minimal therapy and off therapy were considered, CR was achieved by 8 of 9 patients in group A (estimated cumulative rate, 100%) and 19 of 22 patients in group B (estimated cumulative rate, 92.9%) without any statistically significant difference (Table II) . Relapse was seen in 4 of 9 (44.4%) and 7 of 22 (31.8%) patients in groups A and B, respectively. Five of 9 patients in group A (55.6%) and 6 of 22 patients in group B (35.5%) were administered repeated infusions of rituximab, with 3 patients (33.3%) and 2 patients (9.1%), respectively, receiving 2 or more repeat infusions. No significant difference was found between the 2 groups regarding the time to first relapse (P ¼ .33).
In our study CR off therapy was more likely to be achieved by patients receiving rituximab earlier in the disease course (\6 months) and as first-line steroid-sparing adjuvant. Even when accounting for prolonged disease durations, our results were still significant. Given the limits of our sample size, we were unable to account for additional potential cofounders such as disease subtype or the use of different adjuvant therapies. However, previous analyses have failed to show any effect of these confounders on clinical outcomes. 4 Thus, it is unlikely that they contributed to the difference in our observed responses. It is noteworthy that despite the differences in early outcome, there was no difference between the groups in any of the secondary end points. The higher requirement of repeat infusions in group A is skewed by its small sample size and 2 of the patients requiring retreatment for failure to achieve CR. A recent prospective multicenter study encompassing 91 patients with pemphigus has shown that firstline use of rituximab in combination with short-term prednisone makes it possible to achieve CR off therapy in a 3 times greater portion of patients than with use of prednisone alone and was associated with significantly fewer grade 3 and 4 side effects. 5 These findings support the use of rituximab with low-dose corticosteroids as a first-line regimen in pemphigus. 
